申请人:Gil-Ad Irit
公开号:US20100130549A1
公开(公告)日:2010-05-27
The present invention provides a method for treating or preventing a disease or disorder treatable by the inhibition of serotonin reuptake in a patient, and/or norepinephrine reuptake and/or dopamine reuptake in a patient, the method comprising administering to the patient a neurotransmitter reuptake inhibiting-effective amount of at least one compound of the formula A-L-B (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A is a psychotropic derivative; L is a linking group comprising two carbon atoms; and B is an alkyl, alkenyl, alkynyl or aralkyl comprising at least one substituent of the formula Q, wherein: the alkyl, alkenyl, alkynyl or aralkyl is optionally substituted with one or more halogean halogens, hydroxyl, cyano, nitro, amino or thiol; and Q is OR
6
, OC(O)R
6
, C(O)R
6
, C(S)R
6
, CO2R
6
, C(O)SR
6
, C(O)NR
6
R
7
, C(S)NR
6
R
7
, NR
6
R
7
, NR
6
C(O)R
7
, NR
6
C(S)R
7
, NR
6
C(O)NR
7
R
8
, NR6C(S)NR
7
R
8
, NR
6
SO2R
7
, NR
6
SO2NR
7
R
8
, SR
6
, SC(O)R
6
, SC(O)NR
6
R
7
, S(O)R
6
, SO2R
6
, SO2NR
6
R
7
, or NR
6
SO2NR
7
R
8
.
本发明提供了一种治疗或预防患有可通过抑制患者的5-羟色胺、去甲肾上腺素和/或多巴胺再摄取来治疗的疾病或障碍的方法,该方法包括向患者施用公式A-L-B(I)中至少一种化合物的神经递质再摄取抑制有效量,或其药学上可接受的盐、酯或前药,其中A是精神药物衍生物;L是包含两个碳原子的连接基;B是烷基,烯基,炔基或芳基烷基,其中至少有一个取代基为公式Q,其中:烷基,烯基,炔基或芳基烷基可选择性地取代有一个或多个卤素,羟基,氰基,硝基,氨基或硫醇基;Q是OR6,OC(O)R6,C(O)R6,C(S)R6,CO2R6,C(O)SR6,C(O)NR6R7,C(S)NR6R7,NR6R7,NR6C(O)R7,NR6C(S)R7,NR6C(O)NR7R8,NR6C(S)NR7R8,NR6SO2R7,NR6SO2NR7R8,SR6,SC(O)R6,SC(O)NR6R7,S(O)R6,SO2R6,SO2NR6R7或NR6SO2NR7R8。